Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M C Delauche-Cavallier

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
British Journal of Urology|July 1, 1992
Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF GroupP Teillac, M C Delauche-Cavallier, P Attali
British Journal of Urology|November 1, 1993
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF GroupA Jardin, H Bensadoun, M C Delauche-Cavallier, et al.
Lancet (London, England)|October 12, 1991
Alfuzosin for benign prostatic hypertrophyA Jardin, H Bensadoun, M C Delauche-Cavallier, et al.
Lancet (London, England)|June 15, 1991
Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF GroupA Jardin, H Bensadoun, M C Delauche-Cavallier, et al.
British Journal of Urology|May 23, 1998
Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstructionJ M Buzelin, M C Delauche Cavallier, D Martin, et al.
European Urology|January 1, 1997
Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study GroupJ M Buzelin, S Roth, C Geffriaud-Ricouard, et al.
British Journal of Urology|November 1, 1994
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF GroupA Jardin, H Bensadoun, M C Delauche-Cavallier, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|August 12, 1999
QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamineM C Delauche-Cavallier, S Chaufour, E Guérault, et al.
Pathologie-Biologie|March 1, 1989
[Meningococcal arthritis (serogroup A) contracted during a pilgrimage to Mecca]A Trylesinski, M P Le Pennec, M Guibourdenche, et al.
Neurourology and Urodynamics|January 1, 1996
Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder dysfunction. DORALI Study GroupM Perrigot, M C Delauche-Cavallier, G Amarenco, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
British Journal of Urology|July 1, 1992
Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF GroupP Teillac, M C Delauche-Cavallier, P Attali
British Journal of Urology|November 1, 1993
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF GroupA Jardin, H Bensadoun, M C Delauche-Cavallier, et al.
Lancet (London, England)|October 12, 1991
Alfuzosin for benign prostatic hypertrophyA Jardin, H Bensadoun, M C Delauche-Cavallier, et al.
Lancet (London, England)|June 15, 1991
Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF GroupA Jardin, H Bensadoun, M C Delauche-Cavallier, et al.
British Journal of Urology|May 23, 1998
Clinical uroselectivity: evidence from patients treated with slow release alfuzosin for symptomatic benign prostatic obstructionJ M Buzelin, M C Delauche Cavallier, D Martin, et al.
European Urology|January 1, 1997
Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study GroupJ M Buzelin, S Roth, C Geffriaud-Ricouard, et al.
British Journal of Urology|November 1, 1994
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF GroupA Jardin, H Bensadoun, M C Delauche-Cavallier, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|August 12, 1999
QT interval monitoring during clinical studies with mizolastine, a new H1 antihistamineM C Delauche-Cavallier, S Chaufour, E Guérault, et al.
Pathologie-Biologie|March 1, 1989
[Meningococcal arthritis (serogroup A) contracted during a pilgrimage to Mecca]A Trylesinski, M P Le Pennec, M Guibourdenche, et al.
Neurourology and Urodynamics|January 1, 1996
Effect of intravenous alfuzosin on urethral pressure in patients with neurogenic bladder dysfunction. DORALI Study GroupM Perrigot, M C Delauche-Cavallier, G Amarenco, et al.
Pageof 2